Search research articles
Contact Us
Filters
Showing results (41-50 of 91) with videos related to
Page
of 10
Sort By:
BMC Genomics
|
September 25, 2013
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
Emanuele de Rinaldis, Patrycja Gazinska, Anca Mera, et al.
Cancer Immunology Research
|
January 24, 2018
Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
Neidy V Rodrigues, Daniel V Correia, Sofia Mensurado, et al.
Breast Cancer Research : BCR
|
April 8, 2015
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer
Kelly J Soady, Howard Kendrick, Qiong Gao, et al.
Cell Stem Cell
|
September 1, 2010
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
Gemma Molyneux, Felipe C Geyer, Fiona-Ann Magnay, et al.
NPJ Breast Cancer
|
March 6, 2021
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment
Julia Stevenson, Rachel Barrow-McGee, Lu Yu, et al.
Cancer Research
|
October 23, 2013
A novel model of dormancy for bone metastatic breast cancer cells
Rebecca Marlow, Gabriella Honeth, Sara Lombardi, et al.
Cancer Research
|
October 26, 2011
Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers
Sylvain Julien, Aleksandar Ivetic, Anita Grigoriadis, et al.
Cancer Research
|
February 25, 2010
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
Nicholas Turner, Alex Pearson, Rachel Sharpe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancer
Otto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt, Mark Robson, Judy E Garber, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 91) with videos related to
Sort By:
Page
of 10
BMC Genomics
|
September 25, 2013
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
Emanuele de Rinaldis, Patrycja Gazinska, Anca Mera, et al.
Cancer Immunology Research
|
January 24, 2018
Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells
Neidy V Rodrigues, Daniel V Correia, Sofia Mensurado, et al.
Breast Cancer Research : BCR
|
April 8, 2015
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer
Kelly J Soady, Howard Kendrick, Qiong Gao, et al.
Cell Stem Cell
|
September 1, 2010
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
Gemma Molyneux, Felipe C Geyer, Fiona-Ann Magnay, et al.
NPJ Breast Cancer
|
March 6, 2021
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment
Julia Stevenson, Rachel Barrow-McGee, Lu Yu, et al.
Cancer Research
|
October 23, 2013
A novel model of dormancy for bone metastatic breast cancer cells
Rebecca Marlow, Gabriella Honeth, Sara Lombardi, et al.
Cancer Research
|
October 26, 2011
Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers
Sylvain Julien, Aleksandar Ivetic, Anita Grigoriadis, et al.
Cancer Research
|
February 25, 2010
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
Nicholas Turner, Alex Pearson, Rachel Sharpe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancer
Otto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt, Mark Robson, Judy E Garber, et al.
Page
of 10